, Assessment report: vancomcyin containing medicinal products (EMEA/H/A-31/1440). Committee for Medicinal Producst for Human Use, 2017.

C. Liu, A. Bayer, S. E. Cosgrove, R. S. Daum, S. K. Fridkin et al., Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary, Clin Infect Dis, vol.52, issue.3, pp.285-92, 2011.

A. Marsot, A. Boulamery, B. Bruguerolle, and N. Simon, Vancomycin: a review of population pharmacokinetic analyses, Clin Pharmacokinet, vol.51, issue.1, pp.1-13, 2012.

J. A. Roberts, M. H. Abdul-aziz, J. Lipman, J. W. Mouton, A. A. Vinks et al., Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions, Lancet Infect Dis, vol.14, issue.6, pp.498-509, 2014.

T. Tasa, T. Metsvaht, R. Kalamees, J. Vilo, and I. Lutsar, DosOpt: a tool for personalized Bayesian dose adjustment of vancomycin in neonates, Ther Drug Monit, vol.39, issue.6, pp.604-617, 2017.

J. E. Murphy, D. E. Gillespie, and C. V. Bateman, Predictability of vancomycin trough concentrations using seven approaches for estimating pharmacokinetic parameters, Am J Health Syst Pharm, vol.63, issue.23, pp.2365-70, 2006.

J. L. Sanchez, A. R. Dominguez, J. R. Lane, P. O. Anderson, E. V. Capparelli et al., Population pharmacokinetics of vancomycin in adult and geriatric patients: comparison of eleven approaches, Int J Clin Pharmacol Ther, vol.48, issue.8, pp.525-558, 2010.

D. J. Eleveld, J. H. Proost, L. I. Cortinez, A. R. Absalom, and M. M. Struys, A general purpose pharmacokinetic model for propofol, Anesth Analg, vol.118, issue.6, pp.1221-1258, 2014.

D. J. Eleveld, J. H. Proost, H. Vereecke, A. R. Absalom, E. Olofsen et al., An allometric model of remifentanil pharmacokinetics and pharmacodynamics, Anesthesiology, vol.126, issue.6, pp.1005-1023, 2017.

T. G. Short, D. Campbell, and T. D. Egan, Increasing the utility of targetcontrolled infusions: one model to rule them all, Br J Anaesth, vol.120, issue.5, pp.887-90, 2018.

N. Holford, Y. A. Heo, and B. Anderson, A pharmacokinetic standard for babies and adults, J Pharm Sci, vol.102, issue.9, pp.2941-52, 2013.

E. Germovsek, C. I. Barker, M. Sharland, and J. F. Standing, Scaling clearance in paediatric pharmacokinetics: all models are wrong, which are useful?, Br J Clin Pharmacol, vol.83, issue.4, pp.777-90, 2017.

E. Germovsek, C. Barker, and M. Sharland, Clin Pharmacokinet, 2018.

G. B. West, J. H. Brown, and B. J. Enquist, A general model for the origin of allometric scaling laws in biology, Science, vol.276, issue.5309, pp.122-128, 1997.

F. Ceriotti, J. C. Boyd, G. Klein, J. Henny, J. Queralto et al., Reference intervals for serum creatinine concentrations: assessment of available data for global application, Clin Chem, vol.54, issue.3, pp.559-66, 2008.

R. Kullar, S. L. Davis, D. P. Levine, and M. J. Rybak, Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets, Clin Infect Dis, vol.52, issue.8, pp.975-81, 2011.

M. J. Rybak, B. M. Lomaestro, J. C. Rotschafer, R. C. Moellering, W. A. Craig et al., Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists, Clin Infect Dis, vol.49, issue.3, pp.325-332, 2009.

E. J. Zasowski, K. P. Murray, T. D. Trinh, N. A. Finch, J. M. Pogue et al., Identification of vancomycin exposure-toxicity thresholds in hospitalized patients receiving intravenous vancomycin, Antimicrob Agents Chemother, pp.1684-1701, 2018.

J. A. Nelder and R. Mead, A simplex method for function minimization, Computer J, vol.7, pp.308-321, 1965.

B. J. Anderson, K. Allegaert, J. N. Van-den-anker, V. Cossey, and N. H. Holford, Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance, Br J Clin Pharmacol, vol.63, issue.1, pp.75-84, 2007.

A. H. Thomson, C. E. Staatz, C. M. Tobin, M. Gall, and A. M. Lovering, Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations, J Antimicrob Chemother, vol.63, issue.5, pp.1050-1057, 2009.

A. F. Van-der-meer, D. J. Touw, M. A. Marcus, C. Neef, and J. H. Proost, Influence of erroneous patient records on population pharmacokinetic modeling and individual bayesian estimation, Ther Drug Monit, vol.34, issue.5, pp.526-560, 2012.

M. Dolton, H. Xu, E. Cheong, P. Maitz, P. Kennedy et al., Vancomycin pharmacokinetics in patients with severe burn injuries, Burns, vol.36, issue.4, pp.469-76, 2010.

M. De-hoog, R. C. Schoemaker, J. W. Mouton, and J. N. Van-den-anker, Vancomycin population pharmacokinetics in neonates, Clin Pharmacol Ther, vol.67, issue.4, pp.360-367, 2000.

J. A. Roberts, F. S. Taccone, A. A. Udy, J. L. Vincent, F. Jacobs et al., Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens, Antimicrob Agents Chemother, vol.55, issue.6, pp.2704-2713, 2011.

E. D. Adane, M. Herald, and F. Koura, Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections, Pharmacotherapy, vol.35, issue.2, pp.127-166, 2015.

M. Yamamoto, T. Kuzuya, H. Baba, K. Yamada, and T. Nabeshima, Population pharmacokinetic analysis of vancomycin in patients with gram-positive infections and the influence of infectious disease type, J Clin Pharm Ther, vol.34, issue.4, pp.473-83, 2009.

N. Revilla, A. Martin-suarez, M. P. Perez, F. M. Gonzalez, and F. Gatta, Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation, Br J Clin Pharmacol, vol.70, issue.2, pp.201-213, 2010.

D. S. Buelga, M. Del-mar-fernandez-de-gatta, E. V. Herrera, A. Dominguez-gil, and M. J. Garcia, Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies, Antimicrob Agents Chemother, vol.49, issue.12, pp.4934-4975, 2005.

C. Oudin, R. Vialet, A. Boulamery, C. Martin, and N. Simon, Vancomycin prescription in neonates and young infants: toward a simplified dosage, Arch Dis Child Fetal Neonatal Ed, vol.96, issue.5, pp.365-70, 2011.

S. Cristallini, M. Hites, H. Kabtouri, J. A. Roberts, M. Beumier et al., New regimen for continuous infusion of vancomycin in critically ill patients, Antimicrob Agents Chemother, vol.60, issue.8, pp.4750-4756, 2016.

Y. L. Lo, J. G. Van-hasselt, S. C. Heng, C. T. Lim, T. C. Lee et al., Population pharmacokinetics of vancomycin in premature Malaysian neonates: identification of predictors for dosing determination, Antimicrob Agents Chemother, vol.54, issue.6, pp.2626-2658, 2010.

S. E. Medellin-garibay, B. Ortiz-martin, A. Rueda-naharro, B. Garcia, S. Romano-moreno et al., Pharmacokinetics of vancomycin and dosing recommendations for trauma patients, J Antimicrob Chemother, vol.71, issue.2, pp.471-480, 2016.

D. J. Venzon and S. H. Moolgavkar, A method for computing profilelikelihood-based confidence-intervals, Appl Stat J R St C, vol.37, issue.1, pp.87-94, 1988.

D. O. Lonsdale, E. H. Baker, K. Kipper, C. Barker, B. Philips et al., Scaling beta-lactam antimicrobial pharmacokinetics from early life to old age, Br J Clin Pharmacol, 2018.

Å. M. Johansson, N. Hill, M. Perisoglou, J. Whelan, M. O. Karlsson et al., A population pharmacokinetic/pharmacodynamic model of methotrexate and mucositis scores in osteosarcoma, Ther Drug Monit, vol.33, issue.6, pp.711-719, 2011.

S. Hennig, J. F. Standing, C. E. Staatz, and A. H. Thomson, Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis, Clin Pharmacokinet, vol.52, issue.4, pp.289-301, 2013.

W. Junge, B. Wilke, A. Halabi, and G. Klein, Determination of reference intervals for serum creatinine, creatinine excretion and creatinine clearance with an enzymatic and a modified Jaffe method, Clin Chim Acta, vol.344, issue.1-2, pp.137-185, 2004.

L. N. Hannivoort, D. J. Eleveld, J. H. Proost, K. M. Reyntjens, A. R. Absalom et al., Development of an optimized pharmacokinetic model of dexmedetomidine using target-controlled infusion in healthy volunteers, Anesthesiology, vol.123, issue.2, pp.357-67, 2015.

M. Bergstrand, A. C. Hooker, J. E. Wallin, and M. O. Karlsson, Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models, AAPS J, vol.13, issue.2, pp.143-51, 2011.

M. M. Rhodin, B. J. Anderson, and A. M. Peters, Human renal function maturation: a quantitative description using weight and postmenstrual age, Pediatr Nephrol, vol.24, issue.1, pp.67-76, 2009.

G. R. Matzke, G. G. Zhanel, and D. Guay, Clinical pharmacokinetics of vancomycin, Clin Pharmacokinet, vol.11, issue.4, pp.257-82, 1986.

E. A. Calvier, E. H. Krekels, P. A. Välitalo, A. Rostami-hodjegan, D. Tibboel et al., Allometric scaling of clearance in paediatric patients: when does the magic of 0.75 fade?, Clin Pharmacokinet, vol.56, issue.3, pp.273-85, 2017.

F. Thalhammer, F. Traunmuller, E. Menyawi, I. Frass, M. Hollenstein et al., Continuous infusion versus intermittent administration of meropenem in critically ill patients, J Antimicrob Chemother, vol.43, issue.4, pp.523-530, 1999.

J. Samardzic, A. Smits, I. Spriet, I. Soldatovic, A. Atkinson et al., Different vancomycin immunoassays contribute to the variability in vancomycin trough measurements in neonates, Biomed Res Int, 2016.

A. Forrest, R. P. Sweeney, W. Tan, B. H. Segal, and N. Almyroudis, Characterization of vancomycin pharmacokinetics in the adult acute myeloid leukemia population, J Oncol Pharm Pract, vol.18, issue.1, pp.91-97, 2012.

W. Zhao, D. Zhang, M. Fakhoury, M. Fahd, F. Duquesne et al., Population pharmacokinetics and dosing optimization of vancomycin in children with malignant hematological disease, Antimicrob Agents Chemother, vol.58, issue.6, pp.3191-3200, 2014.

W. L. Chiou, The phenomenon and rationale of marked dependence of drug concentration on blood sampling site. Implications in pharmacokinetics, pharmacodynamics, toxicology and therapeutics (Part I), Clin Pharmacokinet, vol.17, issue.3, pp.175-99, 1989.